Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Down 5.18%
As of Monday, October 05, Achieve Life Sciences, Inc.’s ACHV share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Commentary & Analysis
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 6.44%
As of Wednesday, September 30, Achieve Life Sciences, Inc.’s ACHV share price has surged by 6.44%, which has investors questioning if this is right time to sell.Michael Rose
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 7.41%
As of Thursday, September 17, Achieve Life Sciences, Inc.’s ACHV share price has surged by 7.41%, which has investors questioning if this is right time to sell.Michael Rose
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 6.36%
As of Friday, August 21, Achieve Life Sciences, Inc.’s ACHV share price has surged by 6.36%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 5.52%
As of Wednesday, August 19, Achieve Life Sciences, Inc.’s ACHV share price has surged by 5.52%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $726.5 | $237.5 | 42% |
|
| Shares Out (Mil) | 93.5 | 53.9 | 61% |
|
| Institutional Ownership | 96.3% | 93.1% | 69% |
|
| Float (Mil) | 74.7 | 41.4 | 55% |
|
| Beta | 2.25 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 1,329 | 628 | 75% |
|
| Price Change (52-week) |
115.2% | 49.0% | 96% |
|
| Growth | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | (30.0%) | (10.2%) | 14% |
|
| EPS (5yr) | 25.4% | 15.7% | 76 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (51.5%) | (15.7%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 11 | 12 | |
| Current EPS | ($0.193) | ($1.380) | ($0.653) | |
| Month Ago EPS | ($0.193) | ($1.371) | ($0.636) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.160) | ($0.684) | ($0.494) | |
| Year/Year Chg | (75.9%) | 10.0% | (113.1%) | |
| Financials | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($114) | ($44) | 10% |
|
| EPS (TTM) | ($1.809) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($33) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $2 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $8 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $649 | $174 | 36% |
|
| Valuation | ACHV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.27 | na |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (91.5%) | (47.7%) | 6% |
|
| ROE | (845.0%) | (55.0%) | 0% |
|
| Liabilities to Assets | 107.7% | 29.4% | 95% |
|
| F-Score | 2 | 2 | 7% |
|
Achieve Life Sciences, Inc. did not pass any screens on 10/12/2026.
